Johnson Financial Group Inc. Acquires 35,003 Shares of Pfizer Inc. $PFE

Johnson Financial Group Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 40.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 121,497 shares of the biopharmaceutical company’s stock after buying an additional 35,003 shares during the period. Johnson Financial Group Inc.’s holdings in Pfizer were worth $2,945,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the 1st quarter valued at $27,000. Curio Wealth LLC raised its position in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth about $28,000. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the 2nd quarter worth about $29,000. Finally, Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the 2nd quarter valued at about $33,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Guggenheim upped their price objective on Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a report on Monday. Scotiabank began coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.39.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.72 on Thursday. The business has a fifty day moving average price of $24.94 and a two-hundred day moving average price of $24.55. The stock has a market capitalization of $146.21 billion, a PE ratio of 13.68, a P/E/G ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.